Genmab — Juni 2020
-
Patienten, die an dieser Phase-I-Studie teilgenommen haben, hatten zuvor bereits im Schnitt drei andere Therapien erhalten.
Beim Kandidaten Glofitamab, der zuvor als CD20-TCB bekannt war, handelt es sich laut Mitteilung um einen bispezifischen, an T-Zellen andockenden CD20xCD3-Antikörper. -
-
-
-
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind